RUDN Journal of Medicinehttp://journals.rudn.ru/medicine
<p><strong>Editor-in-Chief</strong>: Revaz I. Sepiashvili, MD, Professor</p> <p><strong>Indexation</strong>:&nbsp;Russian Science Citation Index,&nbsp;Google Scholar,&nbsp;Ulrich's Periodicals Directory,&nbsp;WorldCat, East View, Dimensions, DOAJ</p> <p><strong>Open Access &amp;&nbsp;<strong><strong>Publication frequency</strong></strong></strong>: Open Access; quarterly publishing.</p> <p><strong><strong>Peer-Review&nbsp;</strong>&amp; APC</strong>:&nbsp;double blind; no article processing charge.</p> <p><strong>ISSN</strong>: 2313-0245&nbsp;(Print)&nbsp;<strong>ISSN</strong>: 2313-0261&nbsp;(online)</p> <p><em><strong>PUBLISHER</strong>: </em><a href="http://eng.rudn.ru/" target="_blank" rel="noopener noreferrer">Peoples&rsquo; Friendship University of Russia (RUDN University)</a></p>Peoples’ Friendship University of Russiaru-RURUDN Journal of Medicine2313-0245<h4 style="text-align: left;" align="center"><em style="background: none; margin: 0px; outline: none 0px; padding: 0px; vertical-align: baseline; font-family: Arial; color: #101010; font-size: 14px;">The right of authorship belongs to the authors of articles.&nbsp;The authors transfer the rights to use the article (including the use and distribution of an article in the Open Access) to the publisher of the journal on a non-exclusive license (Publishing Agreement (Public Offer)). At the same time, authors remain full rightsholders.</em></h4> <h3 align="center">Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical<br />'RUDN Journal of Medicine'</h3> <p>The Federal State Autonomous Educational Institution of Higher Education "Peoples&rsquo; Friendship University of Russia&rdquo; (RUDN), represented by the Vice-Rector for Scientific Work Nur Serikovich Kirabaev, acting under a Power of Attorney dated № 44-09/16-144 от 27.07.2016 г., hereinafter referred to as the Publisher, on the one hand, hereby offers to the public at large, hereinafter referred to as the Author, on the other hand, hereinafter collectively referred to as the Parties, to enter into this agreement, hereinafter referred to as the Agreement, regarding publication of scholarly materials, hereinafter referred to as the Article, in the Journal named 'RUDN Journal of Medicine', hereinafter referred to as the Journal, under the following terms.</p> <p><strong>1. General Terms and Conditions</strong></p> <blockquote> <p>1.1. Pursuant to Clause 2 of the Article 437 of the Russian Federation Civil Code, this Agreement shall be recognized as the public offer, hereinafter referred to as the Offer. Subject to Article 438 of the Russian Federation Civil Code, this Offer shall be deemed to have been completely and irrevocably accepted after the Author had submitted his/her materials by uploading those onto the network electronic system of the article acquisition for review available at the respective section of the Journal's site at URL: <span data-sheets-value="{&quot;1&quot;:2,&quot;2&quot;:&quot;http://journals.rudn.ru/index.php/medicine/author/submit/1&quot;}" data-sheets-userformat="{&quot;2&quot;:513,&quot;3&quot;:{&quot;1&quot;:0},&quot;12&quot;:0}"><a class="in-cell-link" href="/index.php/medicine/author/submit/1" target="_blank" rel="noopener noreferrer">http://journals.rudn.ru/index.php/medicine/author/submit/1</a></span>&nbsp;on the Information and Communication Network known as the Internet, hereinafter referred to as the Internet.</p> <p>1.2. Pursuant to the Russian Federation effective law as applicable to compliance with the copyright to electronic information resources, no materials from any site, electronic journal or project may be reproduced, in whole or in part, in any form, either in a hard or soft copy, without a prior consent from the Journal's authors and editorial staff, which may be expressed by posting a respective consent (open license&nbsp;<a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" rel="noopener noreferrer">Creative Commons Attribution International 4.0 CC-BY</a>) in the relevant section of the Journal's site on the Internet.&nbsp;<br />Whenever any published materials are used within the context of other documents, a reference to the original source needs to be specified.</p> <p>1.3. The Journal is registered by the Federal Oversight Service for Communications, Information Technologies and Mass Communications (RosKomNadzor).</p> </blockquote> <p><strong>2. Terms Used in This Agreement</strong></p> <blockquote> <p><strong>The Author</strong>&nbsp;is an individual (or individuals) whose creative labor has produced the Article.</p> <p><strong>The Offer Acceptance</strong>&nbsp;means a complete and irrevocable acceptance of the Offer under the terms specified in Clause 3 hereof (the Author accepts the Offer by submitting an application to the Publisher, i.e. by uploading the Article along with support materials onto the network electronic system of the article acquisition for review available at the respective section of the Journal's site at URL: <span data-sheets-value="{&quot;1&quot;:2,&quot;2&quot;:&quot;http://journals.rudn.ru/index.php/medicine/author/submit/1&quot;}" data-sheets-userformat="{&quot;2&quot;:513,&quot;3&quot;:{&quot;1&quot;:0},&quot;12&quot;:0}"><a class="in-cell-link" href="/index.php/medicine/author/submit/1" target="_blank" rel="noopener noreferrer">http://journals.rudn.ru/index.php/medicine/author/submit/1</a></span>&nbsp;on the Internet).</p> <p><strong>The Journal</strong>&nbsp;means an academic periodical named 'BULLETIN of Peoples&rsquo; Friendship University of Russia. Series Medicine'.</p> <p><strong>The Application&nbsp;</strong>means an electronic request of the Author addressed to the Publisher for publishing the Article in the Journal by uploading the Article and support materials onto the network electronic system of the article acquisition for review available at the relevant section of the Journal's site at URL: <span data-sheets-value="{&quot;1&quot;:2,&quot;2&quot;:&quot;http://journals.rudn.ru/index.php/medicine/author/submit/1&quot;}" data-sheets-userformat="{&quot;2&quot;:513,&quot;3&quot;:{&quot;1&quot;:0},&quot;12&quot;:0}"><a class="in-cell-link" href="/index.php/medicine/author/submit/1" target="_blank" rel="noopener noreferrer">http://journals.rudn.ru/index.php/medicine/author/submit/1</a></span>&nbsp;on the Internet).</p> <p><strong>The Publisher</strong>&nbsp;is the Federal State Autonomous Educational Institution of Higher Education "Peoples&rsquo; Friendship University of Russia&rdquo; (RUDN), being the Journal's founder and publisher.</p> <p><strong>The Article's Metadata&nbsp;</strong>means any materials in Russian and English intended to be included into the Science Citation database as per the original version of the Article such as the Article title; authors' details (full last name, first name, patronymic, present employer of each author with indication of the postal code, contact details (e-mail) of each author; abstract; keywords; topical classifications: UDC or any other bibliographic and library classification, and subject indices; bibliography (list of references).</p> <p><strong>The Offer</strong>&nbsp;means this document (offer to the Author) to publish an Article by uploading it onto the site at URL: <span data-sheets-value="{&quot;1&quot;:2,&quot;2&quot;:&quot;http://journals.rudn.ru/index.php/medicine/author/submit/1&quot;}" data-sheets-userformat="{&quot;2&quot;:513,&quot;3&quot;:{&quot;1&quot;:0},&quot;12&quot;:0}"><a class="in-cell-link" href="/index.php/medicine/author/submit/1" target="_blank" rel="noopener noreferrer">http://journals.rudn.ru/index.php/medicine/author/submit/1</a></span>&nbsp;on the Internet.</p> <p><strong>The Publication&nbsp;</strong>means the act of publishing the Article in the Journal.</p> <p><strong>The Journal's Editorial Staff</strong>&nbsp;means a creative team engaged in preparing the Journal for publication.</p> <p><strong>The Editorial Board</strong>&nbsp;is an advisory body of the Journal's Editorial Office.</p> <p><strong>The Article</strong>&nbsp;means a result of fundamental and applied scholarly efforts in the form of a scholarly material, scientific review material, scientific message, bibliographical review on specific topics of the scholarly study, and background information on Russian and foreign scientists submitted by the Author for publication in the Journal.</p> <p><strong>The Parties&nbsp;</strong>mean the Author and the Publisher.</p> <p><strong>The Article Requirements&nbsp;</strong>mean requirements to the materials published in the Journal's section named "To Authors" of the Journal's site at URL: <span data-sheets-value="{&quot;1&quot;:2,&quot;2&quot;:&quot;http://journals.rudn.ru/index.php/medicine/about/submissions#authorGuidelines&quot;}" data-sheets-userformat="{&quot;2&quot;:513,&quot;3&quot;:{&quot;1&quot;:0},&quot;12&quot;:0}"><a class="in-cell-link" href="/index.php/medicine/about/submissions#authorGuidelines" target="_blank" rel="noopener noreferrer">http://journals.rudn.ru/index.php/medicine/about/submissions#authorGuidelines</a></span>&nbsp;on the Internet.</p> <p><strong>The Service&nbsp;</strong>means publication of the Article in the Journal as per the Author's application.</p> </blockquote> <p><strong>3. Subject Matter of the Agreement (Offer)</strong></p> <blockquote> <p>3.1. Subject to this Agreement, the Author shall provide the Publisher at no expense for the copyright duration as stated by the Russian Federation legislation with&nbsp;<strong>a non-exclusive license</strong>&nbsp;for use of the Author-created Article for the purpose of its publication in the Journal.</p> <p>3.2. The rights to use this Article as assigned hereunder shall include but not limited to:</p> <ul> <li>reproduction of the Article or any part thereof, as well as its metadata in Russian and English in any material form whatsoever, including soft and hard copy forms, as an individual work product in periodicals and/or databases (whether local or web-based) owned by the Publisher and/or any other persons at the discretion of the Publisher;</li> <li>dissemination of the Article or any part thereof, as well as its metadata in Russian and English on any media as part of the Journal and/or databases owned by the Publisher or any other persons, at the discretion of the Publisher, or as an individual work product, worldwide via open access or by subscription without payment of any fee to the Author;</li> <li>making public the Article or any part thereof as well as its metadata in Russian and English so that any person could access the Article from any location and at any time of his/her choice (including via the Internet);</li> <li>issuing permissions to use the Article or any part thereof as well as its metadata in Russian and English to any third parties while notifying the Author by publishing the respective information on the Journal's site without payment of any fee to the Author;</li> <li>processing, including translation of the Article (including translation into foreign languages), and use of the processed (translated) Article in any manner specified above;</li> <li>any other rights, not expressly assigned to the Publisher hereunder, including patent rights to any processes, techniques or methods, and other means, described by the Author in the Article, as well as trademark rights, shall be retained by the Author.</li> </ul> <p>3.3. No territorial restrictions will be applied to the use of rights to the Article.</p> <p>3.4. This Agreement shall become effective from the time the Article is submitted to the Journal, i.e. uploaded along with support materials onto the network electronic system of the article acquisition for review available at the relevant section of the Journal's site at URL: <span data-sheets-value="{&quot;1&quot;:2,&quot;2&quot;:&quot;http://journals.rudn.ru/index.php/medicine/author/submit/1&quot;}" data-sheets-userformat="{&quot;2&quot;:513,&quot;3&quot;:{&quot;1&quot;:0},&quot;12&quot;:0}"><a class="in-cell-link" href="/index.php/medicine/author/submit/1" target="_blank" rel="noopener noreferrer">http://journals.rudn.ru/index.php/medicine/author/submit/1</a></span>&nbsp;on the Internet, hereinafter referred to as the Article Upload.</p> <p>3.5. The rights shall be assigned by the Author to the Publisher at no expense, and the Article publication in the Journal shall not result in any financial contribution to the Author.</p> <p>3.6. If the Publisher decides to refuse to publish the Article in the Journal, this Agreement shall cease to be in force. A decision to refuse publication shall be sent to the Author via the e-mail address specified in the Application.</p> <p>3.7. The Publisher undertakes, throughout the currency of this Agreement, to provide to the Author the services associated with publication of the Article on the Journal's site at URL: <span data-sheets-value="{&quot;1&quot;:2,&quot;2&quot;:&quot;http://journals.rudn.ru/index.php/medicine&quot;}" data-sheets-userformat="{&quot;2&quot;:513,&quot;3&quot;:{&quot;1&quot;:0},&quot;12&quot;:0}"><a class="in-cell-link" href="/index.php/medicine" target="_blank" rel="noopener noreferrer">http://journals.rudn.ru/index.php/medicine</a></span>&nbsp;on the Internet.</p> </blockquote> <p><strong>4. General Terms of the Services Provision</strong></p> <blockquote> <p>4.1. The Publisher shall provide the services to the Author only if:</p> <ul> <li>the Author submits all materials compliant with the Offer requirements by way of the Article Upload;</li> <li>the Author Accepts the Offer.</li> </ul> <p>4.2. The services shall be provided to the Author free of charge.</p> <p>4.3. If any materials submitted by the Author are found in breach of rules and requirements of this Offer, the Publisher shall have a right to refuse to publish those.</p> <p>4.4. The Publisher shall not be responsible for any third-party unauthorized use of the data provided by the Author during the currency of this Agreement.</p> </blockquote> <p><strong>5. Rights and Responsibilities of the Parties</strong></p> <blockquote> <p>5.1. The Author warrants that:</p> <ul> <li>he/she is the valid holder of exclusive rights to the Article; rights granted to the Publisher hereunder were not earlier assigned and will not be assigned to any third parties prior to publication of the Article by the Publisher in the Journal;</li> <li>the Article contains all the references to cited authors and/or sources (materials) that are required by the effective copyright law;</li> <li>the Author has obtained all required licenses to results, facts and other borrowed materials used in the Article where the Author is not a copyright holder;</li> <li>the Article does not contain any materials that may not be published in public sources in accordance with the effective Russian Federation statutory instruments, and the Article publication and dissemination will not involve any disclosure of classified (confidential) information, including state secrets;</li> <li>the Author has advised other Co-authors of the terms of this Agreement and has received consents from all the Co-authors to conclude this Agreement under the terms hereunder.</li> </ul> <p>5.2. The Author undertakes to:</p> <ul> <li>submit a manuscript of the Article as per the Requirements to articles;</li> <li>avoid using the soft copy of the Article produced by the Publisher for commercial purposes and in other periodicals;</li> <li>while preparing the Article for publication, the Author undertakes to: <ol type="a"> <li>make edits specified by readers and approved by the Journal's Editorial Office in the text of the Article and/or revise the Article following the Publisher's request, where necessary;</li> <li>proofread the Article within the timeframes specified in the Journal publication schedule;</li> <li>make only such edits in the proof that are minimally required to correct errors made in the Article original and/or introduce factual and momentary changes.</li> </ol> </li> </ul> <p>5.3. The Author is entitled to:</p> <ul> <li>pass to any third party a soft copy of the published Article provided by the Publisher pursuant to Clause 5.4 hereof for the Article to be incorporated, in whole or in part, into a scientific information database or repository in order to promote academic or scholarly investigations or for informational and educational purposes subject to the Author, Journal and Publisher being properly referenced.</li> </ul> <p>5.4. The Publisher undertakes to:</p> <ul> <li>publish the Author's Article, in soft or hard copy form, in the Journal in accordance with the terms hereof;</li> <li>provide the Author with the proof of the Article and make reasonable edits as requested by the Author, where required, following the Journal's Editorial resolution;</li> <li>provide the Author with the soft copy of the published Article by sending it to the Author's e-mail address within 15 business days of the Journal issue's publication;</li> <li>respect the Author's rights established by the effective law, protect those and use best endeavors to prevent any copyright infringements by third parties.</li> </ul> <p>5.5. The Publisher is entitled to:</p> <ul> <li>carry out technical and literary editing of the Article such that its basic content would remain unchanged;</li> <li>review the Article and suggest appropriate changes to the Author, and elect not to publish the Article if the Author fails to introduce such changes;</li> <li>require from the Author and/or other persons that the Journal, Publisher, Author and any other copyright holder, as well as the title of the Article, Journal issue identification and a year of publication as specified in the Journal be properly referenced whenever the Journal and/or the Article, including any individual part or fragment thereof, are used by any of the above-mentioned individuals thereafter;</li> <li>publish preliminary and/or advertising information on the forthcoming publication of the Article in mass media and any other information sources;</li> <li>establish rules (conditions) for acceptance and publication of materials in the Journal. The Journal's Editorial Board, headed by the Editor-in-Chief, shall enjoy an exclusive right to accept and/or reject any materials submitted to the Journal's Editorial Office for publication purposes. No manuscript (tangible medium) submitted by the Author to the Journal's Editorial Office will be subject to return. The Journal's Editorial Staff will not enter into any correspondence regarding the rejection of the Article by the Journal's Editorial Board;</li> <li>suspend provision of services to the Author hereunder temporarily for technical, technological and other reasons preventing the services from being provided for the duration of remedial activities;</li> <li>suspend services hereunder in accordance with civil procedures if: <ol> <li type="a">the Article does not correspond to the topics covered by the Journal or by any part thereof, or the submitted material is found insufficient for the individual publication, or the Article design is found at variance with the requirements imposed;</li> <li>the Author is in breach of any other obligations assumed under the Offer arrangement;</li> </ol> </li> <li>introduce changes to the Offer as per the procedure established by the Offer.</li> </ul> <p>5.6. Unless otherwise provided or stated herein, the Parties shall refer to the effective legislation of the Russian Federation.</p> </blockquote> <p><strong>6. Offer Acceptance and Conclusion of the Agreement. The Term of the Agreement</strong></p> <blockquote> <p>6.1. This Agreement shall become effective when concluded, i.e. when the Author Accepts the Offer by sending an application to the Publisher, that is, by uploading the Article (Article Upload), and remain in effect for five years.</p> <p>6.2. The Offer Acceptance constitutes an Agreement made in writing (Articles 438 and 1286.1 of the Russian Federation Civil Code) under the Offer terms.</p> <p>6.3. Unless any of the Parties sends to the other Party a written notification of the Agreement termination no later than two months prior to the end of the specified five-year period, the duration of the Publisher's copyright to the Work shall be automatically extended by the similar period. The number of extensions is not limited.</p> <p>6.4. The term of the Agreement may not exceed the duration of exclusive rights to the Article pursuant to the Russian Federation legislation.</p> <p>6.5. Whenever the Author assigns (disposes of) its exclusive rights to the Work to any third party, this Agreement shall remain in effect.</p> </blockquote> <p><strong>7. Agreement Modification and Termination Procedure</strong></p> <blockquote> <p>7.1. The Publisher shall have a right to unilaterally modify the terms of this Agreement by giving a prior notice to the Author, at least ten (10) calendar days before such modifications become effective, to the Author's e-mail address specified in the Author's application or via the Journal's site. These modifications shall become effective from the date specified in the respective notice.</p> <p>7.2. If the Author disagrees with any modification in the terms of this Agreement, the Author shall have a right to submit a written notice of his/her withdrawal from this Agreement by uploading it onto the network electronic system of the article acquisition for review, available at the relevant section of the Journal's site at URL: <span data-sheets-value="{&quot;1&quot;:2,&quot;2&quot;:&quot;http://journals.rudn.ru/index.php/medicine/author/submit/1&quot;}" data-sheets-userformat="{&quot;2&quot;:513,&quot;3&quot;:{&quot;1&quot;:0},&quot;12&quot;:0}"><a class="in-cell-link" href="/index.php/medicine/author/submit/1" target="_blank" rel="noopener noreferrer">http://journals.rudn.ru/index.php/medicine/author/submit/1</a></span>&nbsp;on the Internet.</p> <p>7.3. This Agreement may be terminated early:</p> <ul> <li>at any time by mutual agreement of the Parties; or</li> <li>otherwise as stipulated herein.</li> </ul> <p>7.4. The Author shall have a right to cancel this Agreement unilaterally by sending the Publisher a respective notice in writing at least sixty (60) calendar days prior to the intended date of the Author's Article publication in the Journal.</p> <p>7.5. The termination of this Agreement for any reasons shall not release the Parties from responsibility for breach of any Agreement terms during the currency hereof.</p> </blockquote> <p><strong>8. Liability</strong></p> <blockquote> <p>8.1. A Party which has failed to perform its obligations under this Agreement, either in full or in part, shall be held liable pursuant to the Russian Federation legislation in force.</p> <p>8.2. All the data provided by the Author shall be trustworthy. The Author shall be responsible for completeness and reliability of the data provided to the Publisher. The use of untrustworthy information obtained from the Author shall not entail any responsibility upon the Publisher for any adverse effects resulting from its actions based on such untrustworthy information.</p> <p>8.3. The Author shall take full personal responsibility for compliance with the requirements of the Russian Federation law on advertising, protection of copyright and related rights, protection of trademarks and service marks, and protection of consumer rights.&nbsp;<br />8.4. The Publisher shall not be held responsible hereunder for:</p> <ol type="a"> <li>any actions resulting directly or indirectly from the actions of the Author;</li> <li>any loss incurred by the Author whether or not the Publisher was in a position to predict such loss.</li> </ol> <p>8.5. The Publisher shall be relieved from any responsibility for non-compliance with the terms of this Agreement if such non-compliance is a result of a force-majeure event such as an act of state authorities, including adoption of legal instruments, fire, flood, earthquake, other natural calamities, loss of power and/or computer network failure, strikes, civil commotions, riots, and any other similar events.</p> </blockquote> <p><strong>9. Dispute Resolution Procedure</strong></p> <blockquote> <p>9.1. Any disputes and disagreements shall be resolved by the Parties by negotiations, and if the Parties fail to reach an agreement, these shall be resolved in accordance with the effective law of the Russian Federation.</p> <p>9.2. If any disagreements remain unresolved, the Parties shall settle those at the location of the Publisher in accordance with the effective law of the Russian Federation.</p> </blockquote> <p><strong>10. Miscellaneous</strong></p> <blockquote> <p>10.1. Any notifications, messages, requests etc., excluding documents which need to be forwarded in original form pursuant to the Russian Federation legislation, shall be deemed to have been received by the Author, if delivered (sent) by the Publisher via the Journal's site, including by publishing those, by fax or e-mail specified in the Application, or using other communication facilities. The Parties acknowledge validity of notifications, messages, requests etc. delivered (sent) using the above-listed methods.</p> <p>10.2. Where the Publisher becomes subject to any claims related to non-compliance with an exclusive copyright or other intellectual property right of any third party during the writing of the Article or in connection with conclusion of this Agreement by the Author, the Author undertakes to:</p> <ul> <li>immediately upon receipt of a Publisher's notification, take measures to settle disputes with such third party, and, where necessary, join the litigation in favor of the Publisher and use its best endeavors to exclude the Publisher from the defendants;</li> <li>reimburse the legal cost, expenses and loss incurred by the Publisher as a result of application of a pre-award relief and measures for execution of a judgment, and damages paid by the Publisher to any third party for the infringement of exclusive copyright and/or other intellectual property rights, as well as other expenditures incurred by the Publisher as a result of infringement by the Author of any warranties provided hereunder.</li> </ul> <p>10.3. Subject to Article 6 of the Federal Law On Personal Data No. 152-FZ dated July 27, 2006, for the period from the conclusion of this Agreement and until the discharge of Parties obligations hereunder, the Author expresses his/her consent to processing of the following personal data by the Publisher: last name, first name, patronymic; taxpayers identification number (TIN); place and date of birth; citizenship details; ID document details; registration and actual location address; e-mail address; mailing address with postal code; contact phone numbers; fax numbers; and details of the employers.</p> <p>10.4. The Publisher is entitled to process the above personal data for the purpose of this Agreement performance, including for provision of information and reference services to the Author. The processing of personal data shall be understood to mean any handing (operations) with personal data, including collection, systematization, accumulation, storage, refinement (update, alteration), use, distribution (including transfer to third parties), depersonalization, blocking and deletion of personal data in accordance with the effective Russian Federation legislation.</p> <p>10.5. Where permitted by the Russian Federation legislation, the Author is entitled to withdraw his/her consent to processing of personal data as listed in Clause 10.3 by forwarding a respective notice to the Publisher. Upon receipt of such notice, the Publisher has a right to suspend services.</p> <p>10.6. The Author will, on a goodwill basis, submit his/her details (and details of each Co-Author subject to their prior consent) to the Journal's Editorial Office consisting of his/her: last name, first name, patronymic, academic rank, academic degree, job title, employer details (name and mailing address), work phone number and e-mail address for the purpose of its general publication in the Journal along with the Article.</p> </blockquote> <p><strong>11.&nbsp;</strong><strong>Registered Address and Particulars of the Publisher</strong></p> <p>Federal State Autonomous Educational Institution of Higher Education "Peoples&rsquo; Friendship University of Russia&rdquo; (RUDN)</p> <p>Address: 6 Mikluho-Maklaya str., Moscow, 117198, Russian Federation</p> <p>TIN 7728073720, CRR 772801001, PSRN 1027739189323.</p> <p>Vice Rector for Scientific Work&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; N.S. Kirabaev</p>

CHOICE OF MESH IMPLANTS FOR LICHTENSTEIN PLASTIC OF MALE IN REPRODUCTIVE AGEhttp://journals.rudn.ru/medicine/article/view/19669
<p>The article deals with the impact of polypropylene and polyester mesh implants on the sexual function of men of reproductive age after the plastic surgery of the inguinal canal in the Lichtenstein technique. For an adequate comparison of groups of patients with established polypropylene and polyester implants, an algorithm for their examination was developed. For a comprehensive assessment of sexual function in the study, it is divided into two components. Fertility of 155 patients was assessed through the analysis of spermiological studies performed in young patients with inguinal hernia. The possible reason of the immunological form of sterility, against the background of established reticular endoprostheses, a spermiological study in each patient was supplemented with a Mar-test in order to search for antisperm antibodies. To assess the copulative component of sexual function, patients of both groups were questioned according to the questionnaire &ldquo;International Index of Erectile Function, Version 5&rdquo; (ICEF 5). After statistical processing of the data based on the developed algorithm, no statistically significant differences between the groups of patients with established polypropylene and polyester implants were revealed. However, in one patient in the group where polypropylene mesh endoprostheses were used, changes in the spermiological analysis taken after the operative allowance, which can speak of a sharp decrease in the quality of the ejaculate, up to the development of sterility, are revealed. Also, this patient recorded a decrease below the ICEF 5. The results of the study, conclusions were drawn and recommendations were given to practicing surgeons about the possibility of using polypropylene and polyester reticular endoprostheses in plastics of the posterior wall of the inguinal canal in men of reproductive age.</p>A E KlimovV S PopovA A BarchudarovA V Yuriy
Copyright (c) 2018 Klimov A.E., Popov V.S., Barchudarov A.A., Yuriy A.V.
http://creativecommons.org/licenses/by/4.0
2018-12-152018-12-1522324925710.22363/2313-0245-2018-22-3-249-257THE CHOICE OF IMPLANT FOR HERNIOPLASTY OF POSTOPERATIVE VENTRAL HERNIAShttp://journals.rudn.ru/medicine/article/view/19670
<p>According to the literature, up to 50% of laparotomies end with herniation. Therefore, postoperative ventral hernias will not lose their relevance for a long time. The appearance of non-tension hernioplasty by means with synthetic implants helped to solve some issues of hernia: the frequency of relapses in the late postoperative period significantly decreased. However, the number of the complications associated with suppuration of postoperative wounds and seroma in the early postoperative period increased. This leads in the increase of number days of hospital treatment, the need for antibiotic therapy, and accordingly the cost of treatment. In this regard, new types of implants that have the necessary biocompatibility properties are constantly being developed. Also, implants with the possibility of self-griping to the tissues have become more and more relevant in recent years. Self-gripping implants are not only convenient for the operating surgeon - reducing the time of operation, but also don&rsquo;t cause of the chronic pain in the area of operation. However, the problem of surgical treatment of postoperative ventral hernias remains unresolved. The aim of study was to improve the quality of life of patients with postoperative ventral hernias. Was surgery with implants ProgripTM 65 patients. Patients were divided into two groups, taking into account the use of standard implant shape and simulated. The frequencies of surgical complications, duration of surgery and inpatient treatment were compared. The relapse developed in 14.7% and 3.2% of cases, respectively. There were no other significant complications. Conclusion: the simulated implant is anatomically correct and reduces the risk of detachment of the implant from the tissue during stretching.</p>A V ProtasovI O KalyakanovaZ S Kaitova
Copyright (c) 2018 Protasov A.V., Kalyakanova I.O., Kaitova Z.S.
http://creativecommons.org/licenses/by/4.0
2018-12-152018-12-1522325826410.22363/2313-0245-2018-22-3-258-264DISTRUPTION OF SPERMATOGENESIS. MORPHOLOGICAL ASPECTShttp://journals.rudn.ru/medicine/article/view/19671
<p>At the beginning of the 21st century there is a decline in quality of reproductive health of men around the world. In structure of sterile marriage the men's factor of infertility is found out in approximately 40-50% of cases. A little studied question of male infertility is the question of quantity and quality of gametes in convoluted seminiferous tubules. Aim: to study morphological (quantitative and qualitative) changes of a seminiferous epithelium of patients with male infertility. Materials and Methods: 264 patients with male infertility have been examined. Patients with an obstructive form of infertility, with diseases sexually transmitted, with varicocele, with the revealed genetic and immunological factors of infertility have not been included in the research. Patients with a heavy form of pathospermia (n = 112) were taken a testis biopsy before the ICSI cycle (Intra Cytoplasmic Sperm Injection). Further a condition of the seminiferous epithelium of a testis was estimated with the use of light microscopy. Results: Hypoplasy of a seminiferous epithelium was revealed around 34 (30,5%) men, subtotal aplasia of a seminiferous epithelium - around 59 (52,6%) patients, Sertoli Cell-only syndrome - around 12 (10,7%) and tubular atrophy of convoluted seminiferous tubules - around 7 (6,2% ) patients. Conclusions: The morphological research of testis gives the opportunity to define the extent of pathological process at all stages of a spermatogenesis. Only on the basis of studying of features of a spermatogenesis of the specific patient it is possible to make an algorithm of further personal medical and rehabilitation actions.</p>N G Kulchenko
Copyright (c) 2018 Kulchenko N.G.
http://creativecommons.org/licenses/by/4.0
2018-12-152018-12-1522326527110.22363/2313-0245-2018-22-3-265-271EPIDEMIOLOGY OF AGE-RELATED ANDROGEN DEFICIENCY IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIAhttp://journals.rudn.ru/medicine/article/view/19672
<p>Every fourth patient at the age of 50 years, every third patient at the age of 60 years, every second man at the age of 70 years and almost everyone (90%) older than 80 years have Benign prostatic hyperplasia (BPH). Lower urinary tract symptoms developing against the background of BPH are often connected both with manifestations of the hyperplasia of a prostate, and with the age androgenic deficiency (AAD). Aim: To determine the frequency of emergence of age androgenic deficiency of patients with Benign prostatic hyperplasia (BPH). Materials and Methods: 180 patients with clinical signs of Benign prostatic hyperplasia have been examined. All patients were conducted with standard clinical examination: survey, measurement of International prostate symptom score (IPSS), assessment of quality of life (QOL). The research of the androgenic status of patients included clinical assessment of deficiency of androgens with the use of the standard international questionnaire: &ldquo;The questionnaire of Aging Males&rsquo; Symptoms&rdquo; (AMS) and hormonal blood test with determination of level of the general testosterone, follicle-stimulating and luteinizing hormones. Results: There were 118 patients with the low level of the general testosterone (Tgen) (67,7%) of all people. An average level of Tgen was 8,74 &plusmn; 0,9 nmol/l. In group of patients with low testosterone the GPA (grade point average) on a scale of AMS was 47,3 &plusmn; 9,1. Patients with BPH and AAD frequently have the accompanying pathology which is generally presented in such diseases as arterial hypertension, a metabolic syndrome, coronary heart disease, diabetes of the II type, anurolithic disease. Conclusions: Monitoring of the Tgen level is necessary for patients with BPH. Considering the high risk of a combination of BPH with the deficiency of testosterone it is necessary to include in the standard scheme of inspection the hormonal blood test with determination of the Tgen level.</p>P I ChumakovL A MarchenkoI V Kravchenko
Copyright (c) 2018 Chumakov P.I., Marchenko L.A., Kravchenko I.V.
http://creativecommons.org/licenses/by/4.0
2018-12-152018-12-1522327227810.22363/2313-0245-2018-22-3-272-278SELECTION OF METHODS OF COMBINED GERNIOPLASTICS EXTENSIVE MEDIAN HERNIAS TAKING INTO ACCOUNT THE DYSPLASIA OF CONNECTING TISSUEhttp://journals.rudn.ru/medicine/article/view/19676
<p>For the purpose of improvement of results of treatment of extensive median hernias in the choice of ways of the combined hernioplasty at a stage of an electromyography ball assessment of the stigmata of a dysplasia of a connecting tissue, influence of a mesenchymal failure on contractility of abdominal muscles and data of program diagnostics of a collagen found at survey in microscopic preparations of a skin and aponeurosis at 95 surgical patients is introduced. In group 25 (26,4%) of patients with clinically significant level of a dysplasia depression of electroactivity of rectus muscles for 24,7% and the lateral group of the abdominal muscles - for 22,8% is revealed. The microscopy of sites of an aponeurosis among them taped depression of density of laying of a collagen to 31,7% and augmentation of intensity of its staining twice. As a result of the undertaken improvement the way of surgical treatment of median hernias of the extensive sizes which use in clinical practice allows to reduce a share of a dysplasia of a connecting tissue among the reasons of a recurrence of a disease is developed.</p>R I RailianuA A BotezatuG I PodoliniyV A Kryzhanovsky
Copyright (c) 2018 Railianu R.I., Botezatu A.A., Podoliniy G.I., Kryzhanovsky V.A.
http://creativecommons.org/licenses/by/4.0
2018-12-152018-12-1522327928710.22363/2313-0245-2018-22-3-279-287ALLERGEN IMMUNOTHERAPY: EFFICACY, PERSISTENCE, CONSISTENCY, AND COST EFFECTIVENESShttp://journals.rudn.ru/medicine/article/view/19679
Although allergen immunotherapy (AIT) has been used for the treatment of allergic rhinitis (AR), allergic conjunctivitis, asthma, stinging insect hypersensitivity, and atopic dermatitis for over 100 years, it has been slow to gain universal acceptance. With the publication of the “World Health Organization Position Paper, Allergen Immunotherapy” in 1998 which summarized the scientific evidence for the efficacy and long-term benefit of this therapy, it has become an accepted and respected modality of treatment. In this review there are discussed following topics of allergen immunotherapy: the reasons for recommending AIT, mechanism of action, subcutaneous and sublingual methods of application, duration, adherence and cost effectiveness. It is necessary to support, not blame, the patient for nonadherence as it is the responsibility of the patient, the physician, and the health-care system to create an environment in which the patient can be adherent. Nonadherence is multifactorial in most every patient and the physician must address all of the factors if adherence is to be improved. The greatest challenge is taking the time to create an individualized patient-tailored strategy to improve adherence, as one size does not fit all. Adherence is dynamic and selecting the best time to start AIT and assuring that there is close follow-up through AIT years of treatment is essential. The patient who is persistent and consistent in year one of AIT may not continue to be so in year three without added encouragement and support. The health-care systems and professional organizations need to help train physicians and their staff both in efficient and accurate ways to assess nonadherence and in implementing interventions to optimize adherence. The multidisciplinary approach to treating this disease of nonadherence will require the involvement of all healthcare professionals, researchers, professional organizations, insurance companies, and policy-makers.Dana Wallace
Copyright (c) 2018 Wallace D.
http://creativecommons.org/licenses/by/4.0
2018-12-152018-12-1522328830110.22363/2313-0245-2018-22-3-288-301SEVERE ASTHMA IN CHILDRENhttp://journals.rudn.ru/medicine/article/view/19681
<p>The definition of severe asthma is based on the criteria for clinical control, the treatment received, as well as the response to therapy, the assessment of future risk. In severe bronchial asthma, control can be achieved only at the highest possible level of therapy, namely, in treatment corresponding to the 4th or 5th stage. The article highlights the features of the clinical phenotype of severe bronchial asthma in children. Purpose: to identify the predictors of severe phenotype in children, the analysis of clinical and anamnestic features, to study the dynamics of disease control. Materials and methods: a group of patients with different degrees of severity of bronchial asthma aged 3 to 12 years, both sexes, was studied. The clinical aspects of the disease, the dynamics of control over bronchial asthma have been studied. Functional tests were carried out: examination of the function of external respiration, pyclofometry. Data of a specific allergic diagnosis (skin tests with non-bacterial allergens, detection of specific IgE antibodies), self-monitoring tests were studied. Statistical methods used a nonparametric method, a c2 distribution, a Pearson test, using conjugacy tables. Results and discussion: the family female phenotype is a predictor of severe bronchial asthma in patients in this group. The severity of the disease on the background of therapy for five years in a group of patients was revised only in a third of children. With this phenotype, partial control over the disease was achieved. The ineffectiveness of control is associated with the presence of a comorbid background: the pathology of the nervous system, the gastrointestinal tract, endocrine disorders. The severe phenotype of bronchial asthma, independently of age debut, was significantly less frequent than in the case of moderate disease.</p>T R StroikovaO A BashkinaYu L MizernitskiyE N Seliverstova
Copyright (c) 2018 Stroikova T.R., Bashkina O.A., Mizernitskiy Y.L., Seliverstova E.N.
http://creativecommons.org/licenses/by/4.0
2018-12-152018-12-1522330230710.22363/2313-0245-2018-22-3-302-307CLINICAL AND DIAGNOSTIC VALUE OF THE DETERMINANTION OF FRACTALKINE IN ATOPIC DERMATITIS OF CHILDRENhttp://journals.rudn.ru/medicine/article/view/19683
<p>In recent years there has been an increase in the incidence of atopic dermatitis in children. However, despite numerous studies, still remains the problem of objective laboratory diagnosis of this disease, and, respectively, rational pharmacotherapy. Aim. The aim of the study was to improve the diagnostics of allergic skin diseases in children. Materials and methods: the study included 135 children with atopic dermatitis and 29 children in the control group. Clinical and laboratory examination of patients was carried out in accordance with the standards of diagnosis of atopic dermatitis. Additionally, we determined the level fractalkine in blood serum using enzyme immunoassay kit for the quantitative determination fractalkine in biological fluids. Results. For most patients with Ad were a characteristic increase in the level fractalkine in blood serum depending on the severity of the disease. The highest concentrations of the studied CC chemokine is characteristic of severe process. Conclusions. Definition fractalkine in the serum can be used as an indicator of the severity of the pathological process and predicting its future course.</p>M M BenE Ya YanchevskayaO A Mesnyankina
Copyright (c) 2018 Ben M.M., Yanchevskaya E.Y., Mesnyankina O.A.
http://creativecommons.org/licenses/by/4.0
2018-12-152018-12-1522330831310.22363/2313-0245-2018-22-3-308-313CATEGORY OF MARKETING OF RELATIONS IN MEDICAL ORGANIZATIONShttp://journals.rudn.ru/medicine/article/view/19687
<p>The need for intensification of health care, raises the issue of improving the efficiency of medical organizations. The article analyzes the current management technology: &ldquo;marketing relationships in medical organizations&rdquo;. The aim of the research was to find the correct &ldquo;definition of the concept and professional fullness&rdquo; of the content of relationship marketing in medical organizations. The authors defined the marketing of relations in medical organizations as &ldquo;the relationship (mutual relation) of the subjects of medical care at the level of &ldquo;doctor-patient&rdquo;, &ldquo;administration-personnel&rdquo;, &ldquo;relations between medical organizations and counterparts&rdquo;, in order to improve the efficiency of activities and the quality of medical care, patients and medical personnel. The results are obtained on the basis of a comparative analysis of scientific literature data and authors&rsquo; own research. In the formulation of the research, methods of content analysis of bibliographic data, the sociological method and the authors&rsquo; own experience were used. Based on the results of the research, the role of the individual characteristics of patients (gender, age, occupation, relationship to the composition of patients, transport accessibility, organization of admission) in the formation of relations between consumers and providers of medical services is shown. In conclusion, based on the results of the study, the development of marketing relationships at the level of medical organizations of different ownership forms and the need to improve marketing of communications, social networks and distant forms of work with potential and real patients are justified. Conceptual bases of the marketing relationship concept in medical organizations of different ownership forms have been developed.</p>A Yu AbramovD I KichaO V Rukodainiy
Copyright (c) 2018 Abramov A.Y., Kicha D.I., Rukodainiy O.V.
http://creativecommons.org/licenses/by/4.0
2018-12-152018-12-1522331432110.22363/2313-0245-2018-22-3-314-321HUMAN GRANULOCYTOTROPIC ANAPLASMOSIShttp://journals.rudn.ru/medicine/article/view/19692
<p>Natural focal tick-borne infections are widespread in the world and are characterized by a great etiologic diversity. Human granulocytotropic anaplasmosis (HGA), also transmitted by the bite of ticks became relevant in the last century of detection not only in animals but also in humans. The review provides an overview of the incidence of HGA in Russia and in the world, the prevalence of the habitat of mites, the diversity of reservoirs and sources of infection, mechanisms and pathways of transmission of the pathogen Anaplasma phagocytophilum and its biological features. The links and stages of the disease pathogenesis are considered in detail. Scientific data on the clinical course of the disease, the frequency and diversity of various symptoms of the disease, the issues of laboratory and differential diagnosis of anaplasmosis and its place in the nosological structure in patients with fever of unknown origin are discussed. At the same time, choosing a method of laboratory diagnostics it is necessary to take into account that molecular-genetic method (polymerase chain reaction PCR-diagnosis) allows to confirm the diagnosis quickly, while serological methods of research in a greater degree - to put a retrospective diagnosis. The article presents current data on the treatment of disease and methods of HGA prevention and also presents the results of the authors&rsquo; own observations based on the survey of 63 patients. The analysis of Moscow residents treatment about sucking mites is carried out and summarized the incidence of infections transmitted by ixode mites. For the diagnosis of HGA and other tick-borne fever used a technique called polymerase chain reaction. It has been revealed that in Moscow, lime borreliosis occupies a leading place among mites associated with infections 60%, and the share of granulocytic anaplasmosis of a person is only 5% of patients. However, the study of ticks for the presence of HGA pathogens and other natural focal tick infections is carried out in insufficient volume (less than 30%), which should be considered in clinical and laboratory differential diagnosis, as well as preventive measures.</p>Y A KlimovaN A PolovinkinaV V KonnovD S Konnov
Copyright (c) 2018 Klimova Y.A., Polovinkina N.A., Konnov V.V., Konnov D.S.
http://creativecommons.org/licenses/by/4.0
2018-12-152018-12-1522332233110.22363/2313-0245-2018-22-3-322-331REMODELING OF THE TRANSFORMED PHENOTYPE OF CD16+CD32+CD11b+ NEUTROPHILIC GRANULOCYTES OF PATIENTS WITH ATYPICAL CHRONIC BACTERIAL INFECTION IN VITROhttp://journals.rudn.ru/medicine/article/view/19697
<p>The research has shown that the functional state of neutrophilic granulocytes (NG) is determined by the state of NG subpopulation phenotype composition in evaluating the simultaneous expression of CD16, CD32, CD11b membrane markers with considering the density of expressed molecules. The change in NG subpopulations phenotype indicates active or defective inclusion of NG in the immune response in inflammation. Various inducers of endo- and exogenous nature activate NG and promote translocation from cytoplasmic granules and vesicles or expression to the surface cytoplasmic membrane of receptor molecules. In this regard, our interest was in studying the expression peculiarities of CD16, CD32, CD11b NG receptors in patients with atypically occurring bacterial infections (chronic sinusitis) and the possibility of remodeling the NG phenotype under the influence of glucosaminylmuramyl dipeptide (GMDP) and IFN&gamma; in vitro. Subjects of this study were blood samples of patients with chronic sinusitis and conditionally healthy individuals. Flow rate cytometry at CYTOMICS FC500 (Beckman Coulter, USA) was used to evaluate the % NGs expressing CD16, CD32, CD11b, and the fluorescence intensity of these molecules (MFI) before and after incubation with the test substances. Flow cytometry (CYTOMICS FC500, Beckman Coulter, USA) were used to evaluate amount (%) of NGs expressing CD16, CD32, CD11b and mean fluorescence intensity of these molecules (MFI) before and after incubation with the test substances. The studies showed that in patients with chronic sinusitis with persistent recurrent course the presence is characterized by transformed phenotype CD16dimCD32midCD11bbr of CD16+CD32+CD11b+NG subpopulation. We have shown that the revealed changes in the level of expression of trigger membrane receptors do not allow NG to fully engage in inflammatory process and to realize its effector and regulatory functions. Under the influence of GMDP and IFN&gamma; regulatory molecules was demonstrated high mobilization capacity of the studied NGs for functionally significant membrane receptors in realization of various functions.</p>G A ChudilovaI V NesterovaL V LomtatidzeS V KovalevaT V Rusinova
Copyright (c) 2018 Chudilova G.A., Nesterova I.V., Lomtatidze L.V., Kovaleva S.V., Rusinova T.V.
http://creativecommons.org/licenses/by/4.0
2018-12-152018-12-1522333233910.22363/2313-0245-2018-22-3-332-339EMERGENCY PROPHYLAXIS OF EXPERIMENTAL MELIOIDOSIS USING SYNTHETIC IMMUNOMODULATORS AND HETEROLOGOUS VACCINEShttp://journals.rudn.ru/medicine/article/view/19702
<p>Melioidosis is a particularly dangerous infection caused by Burkholderia pseudomallei , against which a vaccine has not yet been created. In this regard, the development of effective treatment regimens and emergency prevention of melioidosis is very relevant. To improve the effectiveness of emergency prophylaxis of melioidosis, synthetic peptides (bestim, imunofan) and thiopoietin preparation glutoxim were used when combined with the antibiotic doxycycline. In addition, in experiments on white mice, the ability of heterologous vaccines (plague and tularemia), used in the emergency prevention mode, to increase the resistance of animals to melioidosis infection was assessed. It was shown that the most effective was imunofan, which, when combined with doxycycline, increased by 20% the survival rate of 5LD50 Burkholderia pseudomallei infection and significantly increased the average life span of mice infected with 5-12 LD50 (p &lt; 0.05). The efficiency of use for stimulation of non-specific resistance to melioidosis of a heterologous plague vaccine EV, once administered 1 day prior to infection, protected 90% of mice from 6 LD50 Burkholderia pseudomallei and 60% - with an increase in the infectious dose of the pathogen of melioidosis up to 15 LD50. The same level of protection from melioidosis was provided by a 3 day course of antibiotic therapy with doxycycline. It was concluded that the tularemia vaccine is not suitable for immunostimulation in melioidosis due to its high residual virulence and reactogenicity.</p>I A KhabarovaS I ZhukovaK A RotovE A SnatenkovA V ToporkovD V Viktorov
Copyright (c) 2018 Khabarova I.A., Zhukova S.I., Rotov K.A., Snatenkov E.A., Toporkov A.V., Viktorov D.V.
http://creativecommons.org/licenses/by/4.0
2018-12-152018-12-1522334035010.22363/2313-0245-2018-22-3-340-350